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Immunomodulatory role of leptin treatment in experimental
sepsis caused by gram negative bacteria
Cemile KOCA1, Havva ŞAHİN KAVAKLI2, Özlem ALICI3

Aim: To investigate the effect of leptin treatment on circulating inflammatory cytokines and on tissue damage in
experimental rat model of gram-negative sepsis.
Materials and methods: Adult male Wistar rats, 28 in total, were randomly divided into 4 groups (n = 7): sham, leptin,
sepsis, and sepsis group treated with leptin (sepsis+leptin). Sepsis was induced by intraperitoneal (ip) injection of 2 ×
1010 CFU of Escherichia coli ATCC 25922. Leptin and sepsis+leptin groups received a single dose ip 0.1 mg/kg leptin,
while sham group received 1 mL of ip saline. Rats were sacrificed 24 h after the induction of sepsis. Blood samples, lung,
and kidney tissues were collected for analysis.
Results: The sepsis group had significantly higher serum TNF-α, IL-6, and endothelin levels than the sham group (P =
0.05, P < 0.001, P = 0.003, respectively). The sepsis+leptin group had significantly lower IL-6 and endothelin levels (P =
0.001 and P = 0.020, respectively), and higher lung and kidney tissue myeloperoxidase activities when compared with
the sepsis group (P = 0.039, P = 0.033, respectively).
Conclusion: According to our results, leptin has a profound influence on sepsis, and to some extent it restricts the
inflammatory events in sepsis.
Key words: Cytokines, leptin, myeloperoxidase, rat, sepsis

Leptin tedavisinin deneysel sepsis modelinde immunmodulator rolü
Amaç: Deneysel gram negatif sepsis oluşturulmuş ratlarda leptin tedavisinin inflamatuar sitokinler ve doku hasarı
üzerindeki etkilerini araştırılmak.
Yöntem ve gereç: 28 adet erkek Wistar cinsi rat randomize olarak 4 eşit gruba ayrıldı; sham, leptin, sepsis ve leptin
tedavisi almış sepsis (sepsis+leptin) grupları. Sepsis, 2 × 1010 CFU ATCC 25922 Escherichia coli suşunun intraperitonel
(ip) verilmesi ile oluşturuldu. Leptin ve sepsis+leptin gruplarına tek doz 0,1 mg/kg ip leptin, sham grubuna eş zamanlı 1
ml ip salin uygulandı. Sepsis indüklendikten 24 saat sonra ratlar sakrifiye edildi. Kan örnekleri leptin, endotelin, TNF-α,
IL-6 ve IL-10 düzeylerinin tespiti için ayrıldı. Akciğer ve böbrek dokuları myeloperoksidaz (MPO) aktivite tayini için
çıkarıldı.
Bulgular: Sepsis grubu sham grubuna göre anlamlı olarak yüksek TNF-α, IL-6 ve endotelin düzeylerine sahipti
(sırasıyla, P = 0,05, P < 0,001, P = 0,003). Sepsis+leptin grubunda IL-6 ve endotelin düzeylerinde sepsis grubuna göre
anlamlı azalma (sırasıyla P = 0,001 ve P = 0,02), akciğer ve böbrek dokusu MPO aktivitelerinde anlamlı artış (sırasıyla
P = 0,039, P = 0,033) görüldü.
Sonuç: Çalışmamızın sonuçları doğrultusunda, leptin ve sepsis arasında kompleks bir ilişki olduğu, leptin uygulamasının
sepsiste görülen inflamatuar olayları bir dereceye kadar baskılayabileceği düşünülmektedir.
Anahtar sözcükler: Sitokin, leptin, myeloperoksidaz, sıçan, sepsis
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Introduction
Severe sepsis is an acute inflammatory reaction
that arises due to the host’s response to infection,
resulting in systemic inflammation and organ failure.
Sepsis is characterized by the redundant release
of multiple inflammatory mediators, including
cytokines, into the blood stream (1).
Although there is an enormous amount of
research, the pathophysiology of sepsis is still poorly
understood. The main pathophysiological feature of
sepsis is the uncontrollable inflammatory response
resulting in an increase in both pro- and antiinflammatory mediators. Increased expression of proinflammatory cytokines such as tumor necrosis factor
(TNF)-α, interleukin (IL)-6, and anti-inflammatory
cytokines such as IL-10 in the circulation are strongly
associated with death (2). Increases in the incidences
of sepsis, high sepsis mortality rates, complex
pathophysiology, and overall difficulties in treatment
make sepsis and sepsis-associated multi-organ failure
a challenge for scientists and clinicians.
Leptin is the 16-kDa protein mainly secreted by
adipose tissue, and is expressed by the obese (ob)
gene, which was named for the obese phenotype of
leptin-deficient ob/ob mutant mice (3). Leptin signals
through the leptin receptor (Ob-R), which is encoded
by the diabetes (db) gene. Primarily, leptin has a role
in suppression of appetite, regulating body weight,
and stimulation of energy expenditure. In addition,
leptin has been shown to involve the regulation of
several physiological processes such as reproduction,
fetal development, angiogenesis, immunity,
hematopoiesis, and bone remodeling (4). Besides
its hormonal function, leptin can be considered as
a cytokine that belongs to the family of long-chain
helical cytokines, and has structural similarity with
IL-6, prolactin, growth hormone, IL-12, IL-15,
and granulocyte colony-stimulating factor, and its
receptor is related to the class I cytokine receptors.
Apart from adipose tissue, leptin receptor is expressed
in other tissues such as bone marrow, spleen, liver,
pancreas, lung, kidney, and on peripheral monocytes,
lymphocytes, and endothelial cells. Because of its
nature as a cytokine, growing evidence shows that
leptin has an important role in the modulation of
the immune response and inflammation. Leptin
exerts proliferative and antiapoptotic activities in a
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variety of cell types, and affects cytokine production,
the activation of monocytes/macrophages, wound
healing, angiogenesis, and hematopoiesis. Moreover,
leptin production is acutely increased during
infection and inflammation (5).
The pathology behind the septic condition in the
patient/animal is not simply about inflammation;
thus, much more is needed to clarify the mechanism
of sepsis, and to optimize present clinical therapies or
develop novel approaches. As at the moment current
data about sepsis and leptin interactions somehow
are contradictory, we think this subject needs more
attention. Under the light of some studies in which
high leptin levels are positively correlated with
survival in septic patients, and anti-inflammatory/
anti-apoptotic actions of leptin would suggest that
leptin may be considered a new potential therapeutic
target for sepsis and sepsis modulated organ failure
(6,7). The aim of the present study was to investigate
the role of leptin in inflammation during Escherichia
coli-induced sepsis, and to examine the potential
association between leptin and various inflammatory
mediators in sepsis.
Materials and methods
Twenty-eight adult male Wistar rats (weight
range: 250 to 300 g) were used for the experiment. All
animals had free access to food and water ad libitum
throughout the study. The rats were divided randomly
into 4 groups, each consisting of 7 animals: the sham
group, the leptin group, the sepsis group, and the
sepsis group treated with leptin (sepsis+leptin group).
The study was approved by the animal research ethics
committee of Fatih University, School of Medicine.
The sham group received a 1 mL intraperitoneal
(ip) injection of 0.9% saline solution. The leptin
group and the sepsis+leptin group underwent a
single dose leptin administration. The leptin (L5037)
was purchased from Sigma Chemical Co. (St. Louis,
MO, USA). It was dissolved according to instructions
and then stored at –20 °C. The leptin was diluted in
phosphate-buffered saline (PBS) (pH 7.4) as 250 μg
in 1 mL before use; then leptin administered groups
were treated with 0.1 mg/kg leptin (ip) within 30 min
of the induction of sepsis (8,9). Sepsis was induced by
ip injection of 2 × 1010 CFU of E. coli ATCC25922. E.
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coli ATCC25922 was grown in a brain-heart infusion
broth. In the logarithmic phase of the growth, the
suspension was centrifuged at 1000 × g for 15 min,
the supernatant was discarded, and the bacteria were
resuspended and diluted into sterile saline. The rats
received an ip inoculum of 1 mL of saline containing 2
× 1010 CFU of E. coli ATCC 25922 (10). All injections
were performed between 0800 and 1000 hours.
All animals were sacrificed using ketamine and
cardiac puncture, 24 h after bacterial challenge. Blood
samples were collected for the determination of
leptin, endothelin, TNF-α, IL-6, and IL-10 levels, and
then were centrifuged at 3000 × g for 10 min. Serum
samples were stored at -80 °C until they were assayed.
Lung and kidney tissue samples were immediately
removed and stored at -80 °C for the determination
of tissue associated myeloperoxidase (MPO) activity,
as indirect evidence of tissue neutrophil infiltration.
The quantitative determination of serum
cytokines, leptin and endothelin levels, Rat
serum TNF-α (Biovendor GmbH, Germany),
IL-6 (BioSource TM, CA, USA), IL-10 (Bender
Medsystems, Vienna, Austria), cytokines levels, and
serum levels of rat leptin (BioSourceTM, CA, USA)
and rat endothelin (Assay Designs, MI, USA), were
measured using commercially available enzyme
linked immunosorbent assay (ELISA) kits according
to the manufacturer’s instructions.
MPO activity such as lung and kidney tissue
MPO activity (MPO1 and MPO2, respectively) was
determined by the method of Koike et al. (11). Tissue
samples were homogenized in 20 mM potassium
phosphate buffer (pH 7.4), and centrifuged at 20,000
× g at 4 °C for 20 min. The pellet was resuspended
in 50 mM potassium phosphate buffer (pH 6.0)
containing 0.5 g/dL hexadecyltrimethyl ammonium
bromide, and frozen at −80 °C. Before assay, batched
samples were thawed, sonicated for 90 s, incubated
for 2 h in a water bath (60 °C), and then centrifuged at
10,000 × g for 5 min. The supernatants were used for
MPO assay. MPO activity was assessed by measuring
the H2O2-dependent oxidation of O-dianisidin.
MPO activity, as 1 unit, was defined as the change in
absorbance at 410 nm in 1 min per 1 g tissue. MPO
activity was expressed as U/g tissue.

Statistical analysis
Statistical analyses were performed by use of SPSS
13.0. The compliance with normal distribution of our
data is examined by Shapiro-Wilk test. Differences
between the groups were statistically analyzed by
2-way analysis of variance (ANOVA). Post-hoc
tests were performed using a multiple comparison
procedure (Tukey test or Tamhane test where
appropriate). Data are expressed as mean ± standard
deviation (SD). A P value of ≤ 0.05 was regarded as
statistically significant.
Results
All the data recorded during our experiment are
shown in the Table.
Intraperitoneal injection of 2 × 1010 CFU of E. coli
ATCC 25922 resulted in an inflammatory stage in the
animals. This was confirmed by an increase in serum
TNF-α and IL-6 levels (P = 0.05, P < 0.001 vs. the sham
group, respectively). The serum endothelin level was
significantly higher in the sepsis group than in the
saline administered rats (P = 0.003). Additionally,
the serum IL-10 level, an anti-inflammatory
cytokine, was decreased, but lung and kidney MPO
activities (MPO1 and MPO2, respectively) were
increased in the sepsis group when compared with
the sham group. However, these differences were
not statistically significant. The leptin treatment
did not show any statistically significant effects on
plasma leptin levels in either the leptin or the sepsis
groups when compared with the sham group. IL-6
levels were significantly higher in the sepsis group
when compared to the leptin group (P < 0.001).
Lung tissue MPO activity was significantly higher in
sepsis+leptin group when compared with the sepsis
(P = 0.039), leptin (P = 0.010), and sham (P = 0.001)
groups (Table). MPO activity in kidney tissue was
significantly higher in the sepsis+leptin group when
compared with the sham (P = 0.003) and sepsis (P =
0.033) groups (Table). TNF-α levels increased in the
leptin group, and even more in sepsis groups when
compared to the sham group. It decreased in the
sepsis+leptin group; however, this decrease was not
significant. Exogenous leptin treatment significantly
reduced IL-6 levels in the sepsis+leptin group (P
= 0.001 vs. the sepsis group) (Table). In the sepsis
group, IL-10 level was lower than the sham group,
and leptin treatment in the sepsis group caused IL-
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Table. Biochemical parameters in the blood, lung, and kidney tissues in groups (n = 7).
Parameters

Sham

Leptin

Sepsis

Sepsis+Leptin

MPO 1 (U/g tissue)

0.52 ± 0.13

0.98 ± 0.27b

1.24 ± 0.49b

2.30 ± 0.80a

MPO2 (U/g tissue)

0.51 ± 0.09

0.75 ± 0.29

0.64 ± 0.08b

0.91 ± 0.18a

Leptin (pg/mL)

384.76 ± 117.39

338.77 ± 115.76b

465.42 ± 193.92b

918.51 ± 336.01a

TNF-α (pg/mL)

250.61 ± 77.93

349.49 ± 133.56

423.77 ± 132.76a

319.34 ± 97.29

IL-6 (pg/mL)

59.63 ± 5.40

61.54 ± 3.85c

85.58 ± 7.78a,b

70.42 ± 7.66a

IL-10 (pg/mL)

212.48 ± 66.98

172.66 ± 35.41

156.21 ± 47.19

195.88 ± 59.98

Endothelin (pg/mL)

0.77 ± 0.32

0.69 ± 0.24

a,b

1.63 ± 0.62

0.96 ± 0.34

MPO1: lung myeloperoxidase activity; MPO2: kidney myeloperoxidase activity; TNF-α: tumor necrosis factor-α; IL-6: interleukin-6;
IL-10: interleukin-10.
Values are given as (mean ± SD)
a
Significant difference compared to sham group (P ≤ 0.05)
b
Significant difference compared to sepsis+leptin group (P ≤ 0.05)
c
Significant difference compared to sepsis group (P ≤ 0.05)

10 levels to increase, although these changes were
not statistically significant. Serum endothelin levels
increased significantly in septic rats when compared
with the rats that received saline. Leptin treatment
significantly reduced this increase in the sepsis+leptin
group (P = 0.020 vs. sepsis group) (Table).
Discussion
Leptin is a multifunctional hormone cytokine
that is involved in the metabolism and immune
response (4,5). The aim of the present study was
to investigate the role of leptin treatment in the
regulation of inflammation during sepsis induced
by bacterial challenge. We have demonstrated that
the exogenous leptin treatment attenuated some of
the inflammatory changes in rats with the bacterial
challenge induced sepsis model. Even though we
generally observed improvements, to some extent,
in septic conditions in leptin treated rats, it is not
easy to evaluate the results of leptin treatment in
inflammation because of the dual role of leptin
both as a pro- and anti-inflammatory effector in the
inflammation. Several studies have demonstrated
an increase in leptin production that occurs during
infection and inflammation, suggesting that leptin
is a part of the cytokine network which governs
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the inflammatory-immune response and the host
defense mechanisms (4). Many studies have shown
that leptin can stimulate various immune cells, and
regulate the production of several pro- and antiinflammatory cytokines through its receptors. In
turn, these proinflammatory cytokines can increase
systemic leptin concentrations in vivo. Leptin mRNA
expression, as well as circulating leptin levels, were
increased by many acute phase factors such as
TNF-α, IL-1 IL-6, during bacterial infection, or
lipopolysaccharide challenge in various studies (12).
Similarly, in our E. coli induced sepsis model, the sepsis
group without exogenous leptin treatment showed
an increase in leptin level; however, this increase was
not statistically significant. Interestingly, leptin levels
were decreased in the leptin group when compared
to the sham group, but the difference was statistically
insignificant. The slight decrease observed in leptin
levels may be related to the pharmacokinetics of
leptin. In the literature, different plasma leptin levels
after exogenous leptin administration at different
time courses were reported (13). Exogenous leptin
treatment may cause up-regulation of membrane
bound leptin receptors, increase the intracellular
uptake of leptin, and decrease circulating leptin
levels. For instance, Cano et al. showed that serum
leptin levels in 0.1 mg/kg single dose leptin treated
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rats decreased to the same levels as the control group
6 h after injection (13). Similar to our finding, Gulen
et al. found lower serum leptin levels in the leptin
treated group than in the sham group after 5 day leptin
treatment (9). A significant increase in serum leptin
levels was observed in the sepsis group treated with
leptin. This significant increase could be an additive
effect of both leptin treatment and inflammation
induced leptin synthesis in septic animals.
The role of leptin in inflammation remains
incompletely understood. Leptin’s action as a
modulator of inflammatory/immune response
is likely to be complex. In various animal and
human experimental studies, both pro- and antiinflammatory effects and controversial results
have been described for leptin. Leptin may
contribute to the development and progression of
autoimmune responses, and leptin deficiency is
associated with reduced inflammation in models of
autoimmune disease, such as experimental allergic
encephalomyelitis, collagen-induced arthritis, and
autoimmune hepatitis (14). On the other hand, leptin
appears to exert anti-inflammatory properties in
models, such as the administration of endotoxin and
TNF-α, and bacterial and viral infections. In these
models, leptin deficiency is associated with increased
susceptibility to the toxicity of proinflammatory
stimuli (15,16). The increased sensitivity to endotoxin
and TNF-α in ob/ob mice and normal mice can
be reversed by leptin administration. Cytokine
production from T lymphocytes is suppressed in
leptin-deficient children and restored by leptin
administration. The general consensus is that leptin
exerts a proinflammatory role, while at the same time
protecting against infections. It has a pivotal role as
an immuno-modulating agent (5,17).
Leptin protects T lymphocytes from apoptosis
and regulates T-cell proliferation and activation
mainly with T-helper cells activity in the cellular
immune response. This anti-apoptotic role of leptin
is especially important in sepsis where apoptosis
of lymphocytes results in decreased septic survival
(4,18). In addition to its effects on T lymphocytes,
leptin also influences monocyte activation,
phagocytosis, expression of adhesion molecules, and
cytokine production. It participates in and crosstalks
with some of the main intracellular signaling pathways

(4). In neutrophils, leptin exerts anti-apoptotic effects
and stimulates complement-mediated phagocytosis,
chemotaxis, and the release of oxygen radicals (4,19).
Leptin stimulates growth hormones, which may be
important in immune homeostasis, given the fact that
this cytokine-like hormone has marked influences
on immune responses by controlling the survival
and proliferation of immune cells (4). Leptin also
affects natural killer cell differentiation, proliferation,
and activation (20). It stimulates production of
proinflammatory cytokines such as TNF-α, IL2, and IL-6 (17). Ob/ob mice (leptin deficient) are
characterized by an impaired antioxidant defense,
as evidenced by a reduced activity of catalase,
glutathione peroxidase, and glutathione reductase
(21). Leptin therapy corrects these abnormalities.
On the other hand, leptin may increase oxidative
stress through multiple mechanisms, especially in
hyperleptinemic states, such as obesity (22).
In our sepsis model, we found decreased IL-10
levels, and significantly increased TNF-α and IL-6
levels in the sepsis group when compared to the
sham group. High proinflammatory cytokine levels
and low anti-inflammatory levels were exerted by
leptin administration in the sepsis group, indicating
the improving effects of leptin in sepsis. Similarly, in
a cerulein-induced acute pancreatitis model, serum
TNF-α and IL-1β levels were found to decrease
significantly 24 h after single-dose exogenous leptin
administration (7). Our understanding of the role
of leptin in inflammation is incomplete. Leptin has
structural similarity with cytokines such as IL-6, and
its receptor is related to the class I cytokine receptors.
Overstimulation of Ob-R by exogenous leptin may
result in a decrease in cytokine levels. In contrast, there
are studies reporting that exogenously administered
leptin increased mortality in different sepsis models,
and was associated with an increased expression
of adhesion and coagulation molecules, cytokine
secretion, macrophage infiltration into the liver and
kidney, and endothelial barrier dysfunction (23).
Endothelin is a vasoactive mediator produced
primarily by endothelial cells; also, it is a potent
vasoconstrictor. Piechota et al. demonstrated that
endothelial dysfunction causes increased endothelin
concentrations in sepsis and its level correlates with
the degree of sepsis severity (24). Endothelin acts
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as one of the many important essential regulators
of muscular tonus of capillary vessels during severe
sepsis associated with increased vascular resistance.
Leptin is closely associated with endothelin (25).
Functional leptin receptors are present on endothelial
cells, so leptin may facilitate endothelin production in
endothelial cells; furthermore, endothelin stimulates
leptin production in adipocytes. However, the actions
of leptin to modulate endothelial function remain
controversial. For instance, some studies suggest
that leptin contributes to endothelial dysfunction or
damage in some pathological states (22). By contrast,
no correlation between leptin and endothelial
function was observed in healthy adolescents and
hypertensive patients (22).
In our study, we found the highest serum
endothelin levels among the sepsis group. This increase
declined significantly in the sepsis group treated with
leptin. High endothelin levels in sepsis indicates poor
prognosis of sepsis. Somehow decreased endothelin
levels in the sepsis group treated with leptin, comparing
to the sepsis group, may improve the detrimental
effects of endothelin in sepsis.
Tissue MPO activity is frequently utilized to
estimate tissue polymorphonuclear leukocytes
accumulation in inflamed tissues as an evidence of
host defense and inflammation. During bacterial
infection, the main functions of neutrophils are to
kill off invading pathogens and the resolution of
associated inflammation. Myeloperoxidase (MPO),
a heme-containing peroxidase, is considered to
contribute substantially to the microbicidal activity
of neutrophils and monocytes through the generation
of a reactive oxidant, mainly hypochlorous acid.
Hypochlorous acid is responsible for the oxygendependent microbicidal activity of phagocytes.
On the other hand, excessive generation of MPOderived oxidants has been linked to tissue damage
in many diseases, especially those characterized by
acute or chronic inflammation (26). As a protection,
organisms develop defense mechanisms against these
generated oxidants. Proteins such as serum albumin,
as well as a number of low molecular weightreducing agents, react rapidly with the highly reactive
products of the MPO system, and prevent them from
reaching a sensitive target of biological importance.
We are thus protected from indiscriminant damage
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by phagocyte-produced oxidants. By definition,
the more reactive the product of the MPO system,
the more likely it will be scavenged (27). Overall,
we should stress that neutrophils are the first cells
to be activated in the host immune response to
infection or injury. They are critical cellular effectors
in both humoral and innate immunity, and a MPO
system that is required for the microbicidal activity
of neutrophils. In the study by Hirche et al., they
demonstrated that mice deficient in MPO were more
likely to die from infection than wild-type mice; so
MPO plays an important role in host antibacterial
defense, ensuring the antimicrobial resistance of the
body (28).
Orlova and Shirshev demonstrated that when
monocytes of the peripheral blood of healthy young
women were incubated with leptin, it stimulated the
activity of MPO secreted by monocytes in cell culture
supernatants (29). Among leukocytes, mononuclear
phagocytes have the highest density of Ob-R
expression, and leptin exerts its effect by binding its
receptor on cell surfaces. During the activation of
monocytes/macrophages, the amount of Ob-R on
their membrane increases considerably (29).
In our study, we observed elevated MPO
activities in lung and kidney tissues in sepsis, and
the further increase of MPO activity in leptin treated
sepsis group means leptin enhances neutrophil
activation and plays a role in combating infections.
The significant high tissue MPO activities in sepsis
may be due to stimulatory effects of inflammation.
Increases in MPO activity after leptin treatment in
the sepsis group may indicate that leptin alleviates
sepsis induced tissue injuries by interfering with
MPO activity. Lin et al. showed that, in the mice
sepsis model, sepsis decreased the ability of the lung,
liver, and kidney to exclude free radicals and bacteria
by suppressing their MPO activity. Leptin treatment
increased MPO activities and reversed the alterations
at the histological level 12 h after injury (30). Yan
et al. reported that exogenous leptin recruitment
protects organ functions and recovers tissue MPO
activity in the mice sepsis model (31). In their sepsis
model, made with cecal ligation and perforation, it
was found that 12 h after injury sepsis suppressed
MPO activity in lung and intestine tissues, indicating
decreased neutrophilic activity of these tissues. Leptin
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and indomethacin treated groups in the experiment
reversed this alteration by increasing tissue MPO
activity at a level similar with sham. Leptin stimulated
MPO to catalyze free radicals into hydroperoxide
in neutrophils through binding with specific leptin
receptors on the cells, and induced a subsequent
recovery of tissue MPO activity to eliminate excess
irritants released by septic injury (32). MPO response
to sepsis was different between our group and Yan
et al. This difference may come from different sepsis
models. On the other hand, contradictory results were
seen in the literature about tissue MPO activity in
leptin treated sepsis models. Gultekin et al. reported
decreased pancreatic and lung MPO activity after
leptin treatment in rats with cerulein-induced acute
pancreatitis (7). In general, overall results suggest that
leptin is required for normal neutrophil complementmediated phagocytosis of bacteria.
Leptin levels are known to increase in critically ill
septic patients, and high levels of leptin are positively
correlated with survival. In one study, plasma leptin
levels were 3-fold higher in patients who survived the
septic episode than in nonsurvivors (32). Recently,
it was demonstrated that leptin deficiency in ob/
ob mice leads to higher mortality and more severe
organ damage in sepsis. Moreover, systemic leptin
replacement improved the immune response to
sepsis. They reported that leptin signaling in the
brain increases survival during sepsis in the leptindeficient, as well as in wild-type mice; in addition,
endogenous CNS leptin action is required for an
adequate systemic immune response, which suggests
a possible therapeutic potential for leptin analogs in
infectious disease (6).

In another study, it was demonstrated that leptin
acts as an endogenous mediator of neuroprotection
during cerebral ischemia via intracellular signaling
pathways, and exogenous leptin administration
protects against ischemic neuronal injury both in
vitro and in vivo cerebral ischemia models (33). In a
review, Signore et al. indicated the beneficial effects
of leptin in a variety of neurodegenerative diseases,
including Parkinson’s and Alzheimer’s disease, and
suggested the possibility of leptin treatment in aging
related neurodegenerative diseases (34).
Our data show that leptin is associated with
inflammation and sepsis. However, due to leptin’s
pro- and anti-inflammatory effects on inflammation,
the role of leptin in the sepsis mechanism and the
use of leptin as a possible therapeutic agent are still
debated. The different sepsis models in studies, the
complexity of sepsis itself, different leptin dosages,
and divergent working groups in experiments may
be the reasons for the various results. Additionally,
leptin’s heterogeneous and opposing actions on
inflammation and sepsis may be another reason for
the conflicting results in publications.
Finally, based on our results, we think that
leptin restricts the inflammatory events in sepsis
to some extent; therefore, leptin may arise as a new
immunotherapeutic target in sepsis.
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